Joe Fletcher | Senior Vice President of Investor Relations |
David Ricks | Chairman & Chief Executive Officer |
Anat Ashkenazi | Chief Financial Officer |
Daniel Skovronsky | Chief Scientific & Medical Officer |
Anne White | President, Lilly Neuroscience |
Ilya Yuffa | President, Lilly International Lilly |
Jake Van Naarden | CEO of Loxo at Lilly |
Mike Mason | President, Lilly Diabetes |
Patrik Jonsson | President of Lilly Immunology & Lilly USA |
Seamus Fernandez | Guggenheim |
Terence Flynn | Morgan Stanley. |
Chris Schott | JPMorgan |
Evan Seigerman | BMO Capital Markets |
Geoff Meacham | Bank of America Merrill Lynch. |
Umer Raffat | Evercore ISI |
Tim Anderson | Wolfe Research |
Steve Scala | Cowen |
David Risinger | SVB Securities |
Kerry Holford | Berenberg |
Mohit Bansal | Wells Fargo |
Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q1 2023 Earnings Conference Call. [Operator Instructions] I would now like to turn the conference over to your host, Joe Fletcher, Senior Vice President of Investor Relations. Please go ahead.
Good morning, and thank you for joining us for Eli Lilly and Company's Q1 2023 Earnings Call. I'm Joe Fletcher, Senior Vice President of Investor Relations.